DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184897

A study on mutation in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex using line probe assay

Rohit Kumar, Shivendra Kumar Shahi, Rakesh Kumar, Balkrishna Mishra, Shailesh Kumar, Raj Kishor Sharma

Abstract


Background: The term tuberculosis describe a clinical illness, which is predominantly caused by Mycobacterium tuberculosis and less common by other species. Infection is transmitted by infected droplets through respiratory route. Early diagnosis and appropriate management is the only way to control the spread of infection. The available diagnostic tools include, smear microscopy, culture and molecular methods. Culture is the gold standard, but it takes around 2-8 weeks to get the result and smear microscopy having less sensitivity. Molecular technique especially Line probe assay can be better option because of high sensitivity and specificity, and directly clinical sample can be used, and result will be made available within same day with sensitivity pattern. Present study was designed to use of LPA for early diagnosis.

Methods: Laboratory based observational study conducted in department of microbiology, IGIMS Patna and TBDC, Patna. Sputum specimens were collected from clinically suspected cases of pulmonary tuberculosis, and subjected to smear microscopy, culture and LPA.

Results: During the study period, 2841 patients were diagnosed as pulmonary tuberculosis. Strain of Mycobacterium tuberculosis complex in, 12% (347) patients were rifampicin and isoniazid resistant, 4% (117) and 3% (86) patients were rifampicin and isoniazid mono-resistant respectively. We found that rpoB MUT3 was the most common mutation in gene associated with rifampicin resistant and katG MUT1gene associated with isoniazid resistant.

Conclusions: Present study support the use of LPA for early diagnosis of smear positive as well as smear negative pulmonary tuberculosis cases. Resulting early diagnosis and appropriate management of patients.


Keywords


Culture, Drug resistant, Line probe assay, Pulmonary tuberculosis, Smear microscopy

Full Text:

PDF

References


Barberis I, Bragazzi N, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58:E9-E12.

Sunil S, Abhishek M, Sunil KD, Harpal S, Rakesh Y, Khushwinder S, et al. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis. 2013;13:137.

Isaakidis P, Das M, Kumar AMV, Peskett C, Khetarpal M. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS ONE. 2014;9(10):e110461.

Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients’ smear-negative for acid-fast bacilli. Lancet. 1999.353:444-49.

Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol. 1997;35:719-23.

Seifert M, Catanzaro D, Catanzaro A, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015;10:e0119628.

Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. Analysis of the oxyR-ahpC region in isoniazid-resistant and-susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrobial Agents Chemo. 1997;41(3):600-6.

WHO. Molecular line probe assays for rapid screening of patients at risk of MDR-TB, Policy Statement, WHO, 2008, Available at: http://www.who.int/tb/featuresarchive/policy statement.pdf.

Peres RL, Maciel EL, Morais CG, Ribeiro FC, Vinhas SA, Pinheiro C, et al. Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. Int J Tuberc Lung Dis. 2009;13:1572-75.

Revised National Tuberculosis Control Programme (RNTCP). DOTS-Plus guidelines. New Delhi: Central TB Division Directorate General of Health Services; 2010 January. Available at: health.bih.nic.in/Docs/Guidelines/Guidelines-DOTS-plus.pdf.

Hain Lifescience GmbH. GenoType MTBDRplus version 2.0 [9] product insert. Nehren, Germany. Available at: http://www.hain-lifescience.de/en/instructions-for-use.html.

Abyot M, Abebaw K, Zelalem Y, Zekarias D, Shewki M, Bazezew Y. et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infectious Dis. 2017;17:280.

Marilyn MN, Mahasampath G, Christopher DJ, Priscilla R, Joy SM. The diagnostic utility of line probe assays for multidrug-resistant tuberculosis. Pathogens Global Health. 2016;110(4and5):194-9.

Prabha D, Nikita P, Shaina B M, Aparna C, Kudsia A, Reeta V. Line probe assay for detection of Mycobacterium tuberculosis complex: An experience from Central India. Indian J Med Res. 2017;145(1):70-3.

Sunita T, Rajesh K, Surya DS. Prevalence of multidrug resistant pulmonary tuberculosis in North Bihar. J Clin Diag Res. 2015;9(11):LC09-LC12.

Ramachandran R, Nalini S, Chandrasekar V, Dave P V, Sanghvi A S, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuber Lung Dis. 2009;13(9):1154-60.

Ejaz M, Siddiqui A R, Rafiq Y, Malik F, Channa A, Mangi R, et al. Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: Identification of at risk groups. Trans R Soc Trop Med Hyg. 2010;104(8):511-17.

Naserpour T, Naderi M, Mohagheghefard F A, Sharifi M B, Rezai E. Drug resistance of mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in South Eastern of Iran. J Medical Sciences. 2006;6:321-24.

Raizada N, Sachdeva KS, Chauhan DS, Malhotra B, Reddy K, Dave PV, et al. A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One. 2014 Feb 19;9(2):e88626.

Nontuthuko E, Lesibana A, John F, Ruth M, Nontombi M. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infectious Dis. 2017;17:795.